Your guide to Open Access publishing and Open Science

OncomiRs – New Open Access Journal in microRNAs and cancer biology

Author: No Comments Share:

Open Access provides scientists from around the world with new opportunities to publish their research articles and books from specialized fields of science and to make them available for free to all who want to read them. It also helps to increase the visibility and the level of citation. The number of scientists choose to publish their works in Open Access is visibly growing, and that results in the rapid explosion of niche OA journals. One of the good examples for the latter is a recently released fully peer-reviewed journal: OncomiRs.

With scientists chipped away by niche journals that offer more in-depth coverage of particular topics – OncomiRs reflects the trend towards highly specialized publications (sometimes referred to as verticals)- in which readers can find a research relevant to the interdisciplinary nature of microRNAs and cancer biology. The OncomiRs publishes original research articles and reviews covering all the basics aspects of the microRNAs in tumor formation and development as well as in the regulation of cellular processes such as apoptosis, cell cycle control, metastatic dissemination, cellular senescence and immortalization. A particular attention is given to microRNA-controlled regulation of cellular oncogenes and tumor suppressor genes.

At this point, you can already read the first article from the A. Harel-Bellan’s lab from Paris Sud University in France. The paper “Mir-205 modulates acinar size and morphology of transformed breast epithelial cells” studied the function of miR-205 in cellular formation of breast cancer. From the abstract:

“In 3D cultures, breast epithelial cells form lobular acini that structurally resemble breast alveoli in vivo. Enlarged acini with modified acinar morphology are characteristic of transformed and/or cancer breast cells. A genome-wide miRNA expression screen comparing non-transformed and tumorigenic MCF10A cell lines identified miR-205 as a potential modifier of acinus size. In support of this hypothesis, miR-205 was found overexpressed in transformed and tumorigenic MCF10 cells. We showed that forced expression of miR-205 in non-transformed MCF10A cells increased the size of acini, whereas miR-205 antisense oligonucleotides restored a normal morphology. MiR-205 did not modify cell proliferation but rather inhibited apoptotic cell death. Moreover, miR-205 targets ZEB1, an inhibitor of E-cadherin. E-cadherin was induced upon miR- 205 overexpression. Downregulating E-cadherin restored normal acinar morphology in miR-205 expressing cells, consistent with E-cadherin being involved in the miR-205-dependent acini phenotype.”

OncomiRs seems to be a perfect opportunity to publish the article in such a narrow, but also very interesting field, as microRNAs and cancer biology.

OncomiRs publisher is Versita. The journal already uses heavy publicity to attract readers: the above mentioned article has been picked up and discussed on numerous portals, such as:

http://www.medilexicon.com

http://www.science20.com/

http://www.sciencecodex.com

http://www.medicalnewstoday.com/

http://www.sciencedaily.com

http://www.topix.com/forum/science/genetics

http://healthcareupdates.com

http://esciencenews.com

http://www.reservehealth.com

http://breast-cancer.alltop.com

http://www.thebreastcancerdaily.com/

http://www.sciencedaily.com

http://www.newsnow.co.uk

http://todaysworldnews.com

http://www.medindia.net/

http://cancernewsdaily.net

and made it to top stories posted on www.medicalnewstoday.com

More details on the journal and how to submit can be found on the OncomiRs website.

Previous Article

Journal publishers’ prices are too high, even for the University of Harvard

Next Article

How often do authors pay APCs?

You may also like

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.